Abstract:Introduction Hyperplastic arterial remodelling is characterized by intima-media thickening, lumen narrowing, inflammation and increased extracellular matrix (ECM) deposition. Chondroitin sulfate (CS) glycosaminoglycans, the unbranched polysaccharide chains of proteoglycans, are important components of ECM. We previously found CS accumulated in adversely remodelled heart and artery, aggravating cardiac deterioration. Objective We aim to explore a therapeutic strategy to interfere with CS synthesis and investigate its potential in ameliorating hyperplastic arterial remodelling. Methods Through single-cell RNA sequencing of non-cardiomyocytes cardiac cells from mouse myocardial infarction model, chondroitin sulfate synthase 1 (CHSY1) was identified as the primary CS synthase and was increased during disease progression. A Chsy1 knockout (KO) mouse strain was generated. Fibrosis and arterial remodelling were induced using: (i) 4 weeks of angiotensin II/phenylephrine (AngII/PE) infusion through subcutaneous osmotic minipumps; and (ii) transverse aortic constriction surgery. To assess the therapeutic potential of CHSY1 inhibition in ameliorating hyperplastic arterial remodelling, Chsy1 was knockdown by dsiRNA post disease onset. Mechanism of action was investigated using primary vascular smooth muscle cells (VSMCs). Results Chsy1 KO reduced CS and its stereoisomer dermatan sulfate in the heart to 42 ± 22% and 36 ± 7% respectively, whereas other types of glycosaminoglycans remain intact. KO mice were protected against phenotypes of hyperplastic arterial remodelling induced by the two disease models in both the coronary and carotid arteries. For example, 90.1% of coronary arterial fibrosis and 79.7% of macrophage infiltration induced by AngII/PE was declined in KO mice compared to WT mice, while cardiac function as stroke volume was augmented by 41.3%. Concomitantly, carotid arterial wall thickening was lower by 36.5% and distensibility was higher by 36.7%, validating Chsy1 as a potent target. As a therapeutic approach, weekly intravenous injection of dsiRNA achieved Chsy1 reduced to 30.2 ± 5.5% in the carotid artery and 72.5 ± 4.7% in the heart. Post disease onset, Chsy1 KD therapy reduced fibrosis by 59.9% in the coronary artery (P = 0.006) and improved stroke volume by 25.6% (P = 0.036). The structural integrity and function of carotid arteries were well-reserved, manifesting as improved distensibility (29%, P = 0.016), increased elastin/perimeter ratio (15%, P = 0.002), and reduced macrophage infiltration (38%, P = 0.029). In vitro, CHSY1 inhibition suppressed migration and cytokine production of macrophages, fibroblast-to-myofibroblast transition, and VSMC hyperproliferation. NOTCH3 signalling was found to be positively correlated with CHSY1 modulation. Conclusions We demonstrated that inhibiting CHSY1 is necessary and sufficient to block CS synthesis. Chsy1 KD by dsiRNA is an effective therapy to ameliorate hyperplastic arterial remodelling.

Primary Research on the Changes of Contents and Molecular Structures of Chondroitin Sulfate in Aortic Dissection

Content and Structure of Chondroitin Sulfate in Aortic Dissecting Aneurysms and Its Role

Research Progress on Sulfating Modification of Polysaccharides and Its Anticoagulant Activity

Alterations of elastin and elastic fibers in tunica media of ascending aorta in patients with aortic dissection

Effects of Diallyl Sulphide in Chondrocyte and Cartilage in Experimental Osteoarthritis in Rabbit

Study on Proteomics-Based Aortic Dissection Molecular Markers Using iTRAQ Combined With Label Free Techniques

Acidic glycosaminoglycans in human atherosclerotic cerebral arterial tissues

Molecular structure analysis of ascending aorta aneurysm upon atherosclerosis

Changes in aortic collagen in β-aminopropionitrile-induced acute aortic dissection

Altered expression of chondroitin sulfate structure modifying sulfotransferases in the articular cartilage from adult osteoarthritis and Kashin-Beck disease

Global proteomic analysis reveals lysine succinylation contributes to the pathogenesis of aortic aneurysm and dissection

Mechanical and Histological Characteristics of Aortic Dissection Tissues

The Expression of Matrix Metalloproteinase-9 and the Pathological Changes of Vascular Smooth Muscle Cell in Patients with Acute Ascending Aortic Dissection

Changes in the gut microbiome of patients with type a aortic dissection

Increased Collagen Deposition and Elevated Expression of Connective Tissue Growth Factor in Human Thoracic Aortic Dissection.

Structural Characterization and in Vitro Antioxidant Activities of Chondroitin Sulfate Purified from Andrias Davidianus Cartilage.

Comparison of TGF-β1 distribution and expression in aortic wall of thoracic aortic dissection versus aneurysm

Inhibiting chondroitin sulfate synthase 1 ameliorates hyperplastic arterial remodelling

Swelling of interlamellar GAGs/PGs as an initiation mechanism for aortic dissection: constitutive modeling and numerical simulations

Atherosclerotic Calcifications Have a Local Effect On the Peel Behavior of Human Aortic Media

The Role of Matrix Metalloproteinases in Thoracic Aortic Disease: Are They Indicators for the Pathogenesis of Dissections?